Halia Therapeutics prezante done jodi a sou pwogram inhibitor NLRP3 li nan 10yèm Somè Devlopman Medikaman Neurodegenerative Anyèl jodi a.
Doktè David J. Bearss, Prezidan, ak Direktè Jeneral Halia Therapeutics, mete aksan sou rezilta ki montre kouman lè l sèvi avèk yon apwòch vize allosterik nan yon eleman nan konplèks NLRP3 la pèmèt konsepsyon yon nouvo klas konpoze ki vize tou de deklanchman ak fonksyon NLRP3. Terapi ti molekil sa yo gen potansyèl pou yo vize anpil maladi sistemik enflamatwa ak maladi newolojik. Prezantasyon Dr. Bearss te gen dwa, "Vize NLRP3 Enflamasome pou Tretman Maladi alzayme a." Somè a te fèt nan Boston Park Plaza, Boston, Massachusetts, soti 28 jiska 30 mas 2022.
“Done ak estrateji yo prezante jodi a reprezante yon nouvo paradigm pou vize NLRP3. Jared Bearss, COO Halia a, di Jared Bearss. "Kapasite pou tou de anpeche asanble a ak ankouraje demonte konplèks NLRP3 inflammasome reprezante yon opòtinite enpòtan pou bay nouvo terapi pou pasyan ki soufri maladi newolojik ak enflamatwa."
KISA POU RETIRE NAN ATIK SA A:
- Bearss, President, and CEO of Halia Therapeutics, highlighted results demonstrating how using an allosteric targeting approach to a component of the NLRP3 complex enabled the design of a new class of compounds that target both NLRP3 activation and function.
- “The ability to both inhibit the assembly and promote the disassembly of the NLRP3 inflammasome complex represents a significant opportunity to provide new therapeutics for patients suffering from neurological and inflammatory diseases.
- We are very excited about discovering allosteric modulators of the NLRP3 inflammasome, and we are progressing multiple programs toward the clinic using this targeting strategy,”.
